Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92


Impact of subventricular zone irradiation on outcome of patients with glioblastoma.

Mathew BS, Kaliyath SB, Krishnan J, Bhasi S.

J Cancer Res Ther. 2018 Oct-Dec;14(6):1202-1206. doi: 10.4103/jcrt.JCRT_295_17.


Increased subventricular zone radiation dose correlates with survival in glioblastoma patients after gross total resection.

Chen L, Guerrero-Cazares H, Ye X, Ford E, McNutt T, Kleinberg L, Lim M, Chaichana K, Quinones-Hinojosa A, Redmond K.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):616-22. doi: 10.1016/j.ijrobp.2013.02.014. Epub 2013 Mar 26.


Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis.

Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ.

Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):609-15. doi: 10.1016/j.ijrobp.2013.01.009. Epub 2013 Feb 22.


Dose-escalated intensity-modulated radiotherapy and irradiation of subventricular zones in relation to tumor control outcomes of patients with glioblastoma multiforme.

Kusumawidjaja G, Gan PZ, Ong WS, Teyateeti A, Dankulchai P, Tan DY, Chua ET, Chua KL, Tham CK, Wong FY, Chua ML.

Onco Targets Ther. 2016 Mar 2;9:1115-22. doi: 10.2147/OTT.S96509. eCollection 2016.


Relationship between survival and increased radiation dose to subventricular zone in glioblastoma is controversial.

Elicin O, Inac E, Uzel EK, Karacam S, Uzel OE.

J Neurooncol. 2014 Jun;118(2):413-419. doi: 10.1007/s11060-014-1424-3. Epub 2014 Mar 26. Erratum in: J Neurooncol. 2014 Jun;118(2):421.


Subventricular zones: new key targets for glioblastoma treatment.

Khalifa J, Tensaouti F, Lusque A, Plas B, Lotterie JA, Benouaich-Amiel A, Uro-Coste E, Lubrano V, Cohen-Jonathan Moyal E.

Radiat Oncol. 2017 Apr 20;12(1):67. doi: 10.1186/s13014-017-0791-2.


Influence of incidental radiation dose in the subventricular zone on survival in patients with glioblastoma multiforme treated with surgery, radiotherapy, and temozolomide.

Foro Arnalot P, Pera O, Rodriguez N, Sanz X, Reig A, Membrive I, Ortiz A, Granados R, Algara M.

Clin Transl Oncol. 2017 Oct;19(10):1225-1231. doi: 10.1007/s12094-017-1659-5. Epub 2017 Apr 7.


Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.

Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L.

Front Oncol. 2018 Oct 4;8:426. doi: 10.3389/fonc.2018.00426. eCollection 2018.


Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma?

Gupta T, Nair V, Paul SN, Kannan S, Moiyadi A, Epari S, Jalali R.

J Neurooncol. 2012 Aug;109(1):195-203. doi: 10.1007/s11060-012-0887-3. Epub 2012 May 4.


Influence of glioblastoma contact with the lateral ventricle on survival: a meta-analysis.

Mistry AM, Hale AT, Chambless LB, Weaver KD, Thompson RC, Ihrie RA.

J Neurooncol. 2017 Jan;131(1):125-133. doi: 10.1007/s11060-016-2278-7. Epub 2016 Sep 19. Review.


Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone.

Adeberg S, König L, Bostel T, Harrabi S, Welzel T, Debus J, Combs SE.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):886-93. doi: 10.1016/j.ijrobp.2014.07.027. Epub 2014 Sep 11.


Location of subventricular zone recurrence and its radiation dose predicts survival in patients with glioblastoma.

Weinberg BD, Boreta L, Braunstein S, Cha S.

J Neurooncol. 2018 Jul;138(3):549-556. doi: 10.1007/s11060-018-2822-8. Epub 2018 Mar 15.


Do Increased Doses to Stem-Cell Niches during Radiation Therapy Improve Glioblastoma Survival?

Adeberg S, Harrabi SB, Bougatf N, Bernhardt D, Mohr A, Rieber J, Koelsche C, Rieken S, Debus J.

Stem Cells Int. 2016;2016:8793462. doi: 10.1155/2016/8793462. Epub 2016 Jun 27.


Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.


Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.

Iuchi T, Hatano K, Kodama T, Sakaida T, Yokoi S, Kawasaki K, Hasegawa Y, Hara R.

Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):793-800. doi: 10.1016/j.ijrobp.2013.12.011. Epub 2014 Feb 1.


Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.

Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA.

Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):71-7.


Relationship of glioblastoma multiforme to the subventricular zone is associated with survival.

Jafri NF, Clarke JL, Weinberg V, Barani IJ, Cha S.

Neuro Oncol. 2013 Jan;15(1):91-6. doi: 10.1093/neuonc/nos268. Epub 2012 Oct 24.


Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.

Seidlitz A, Siepmann T, Löck S, Juratli T, Baumann M, Krause M.

Radiat Oncol. 2015 Aug 16;10:172. doi: 10.1186/s13014-015-0478-5.


Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.


The impact of surgery on the efficacy of adjuvant therapy in glioblastoma multiforme.

Brzozowska A, Toruń A, Mazurkiewicz M.

Adv Clin Exp Med. 2015 Mar-Apr;24(2):279-87. doi: 10.17219/acem/40456.

Supplemental Content

Support Center